Friday, 3 January 2020

Latest Study Offers Detailed Insights on Nasal Drug Delivery Market 2019

Market Scenario
The global nasal drug delivery market is expected to grow significantly over the forecast period. The global market was valued at approximately USD 52,998.5 million in 2018 and is projected to grow with 6.6% CAGR over the forecast period.
Nasal drug delivery is administration of drug through the nasal track to treat various respiratory problems such as paranasal sinuses, nasal infection, and other nasal problems. It is an effective delivery method for medicines that are active in low doses.
Factors such as the painless drug administration, development of new technological nasal drug delivery devices, and the increasing number of patient population with respiratory problem are expected to drive the market growth. Moreover, nasal drug delivery devices are easily accessible and suitable for self-medication it has received positive response from patient population, clinicians, and pharmaceutical scientists. 
However, factors such as low bioavailability, nasal irritation, and irreversible damage of cilia of cell is expected to hamper the market growth.
Segmentation
The global nasal drug delivery market has been segmented into drug type, dosage form, basis of system, delivery technologies, therapeutic applications, end users, and region.
Based on drug type, the global market has been segmented into anesthetics, antibiotics, pain relief drugs, calcium supplements, vasoconstrictors, antihistamines, and others.
Based on dosage form, the global market has been segmented into drops, sprays, powder, gels, and ointments.
Based on the basis of system, the global nasal drug delivery market has been segmented into unit dose, multi-dose, and metered dose.
Based on delivery technologies, the global market has been segmented into spray, nebulizers, inhalers, and others.
Based on therapeutic applications, the global market has been segmented into rhinitis, asthma, nasal congestion, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and others.
The global market, by end user, has been divided into home care settings and hospitals & clinics.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The nasal drug delivery market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European nasal drug delivery market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The Asia-Pacific nasal drug delivery market has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The nasal drug delivery market in the Middle East & Africa has been segmented into the Middle East and Africa. The increasing development in healthcare infrastructure and growing economy in countries such as Kuwait, Iran, Israel, and Iraq drive the market growth in this region. 

Key Players

GlaxoSmithKline Plc. (UK), AstraZeneca (UK), Pfizer, Inc. (US), Becton Dickson & Company (US), Dr. Reddy’s Laboratories Ltd. (India), Sanofi-Aventis (UK), Merck & Co. (US), Cadila Pharmaceuticals (India), AEGIS THERAPEUTICS LLC (US), Novartis AG (UK) , Johnson & Johnson Services, Inc (US) and 3M COMPANY (US) are some of the key players in the global nasal drug delivery market.
Regional Market Summary
Geographically, the market has been segmented, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the global nasal drug delivery market owing to an increasing prevalence of rhinitis, congestion, sinusitis, and respiratory allergic reactions.
Additionally, the well-developed healthcare sector and presence of a large number of medical device companies in this region boosts the market growth. According to the Centers for Disease Control and Prevention January 2017, 30.8 million adults were diagnosed with sinusitis in the US.
Europe is expected to hold the second-largest position in the global nasal drug delivery market. The presence of a large patient population suffering from chronic disorders, increasing technological advancement in the healthcare industry, and growing mergers and acquisitions between healthcare companies drives the market growth in this region.
Alabama Nasal Drug Delivery Association (ADMEA) is a Europe based non-profit organization involved in providing home medical equipment. The presence of such organization in Europe enhances the market growth during the forecasted period.
Asia-Pacific is expected to be fastest-growing region owing to the growing geriatric population and increasing incidences of allergy diseases, which is a common cause of respiratory problems in developing countries.
The Middle East & Africa holds the least share of the market. A majority of the market share of this region is expected to be held by the Middle East due to growing government initiatives for the healthcare sector in this region.
Browse Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/nasal-drug-delivery-market-2696
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Thursday, 2 January 2020

Precision Medicine Market in depth study and analysis published, 2019

The major market driving factor for precision medicine are patient’s involvement in personal healthcare, integration of wireless technologies with portable healthcare devices, and increase in genetic diseases (due to mutation, UV rays) among others.
The global precision medicine market was valued at $38.92 billion in 2015, and is expected to reach $88.64 billion by 2025. Thus the market is expected to perform a growth at a CAGR of 12.48% from 2015 to 2025.
Precision medicine evolved from the concept that same medicine cannot function equally for two different individuals with the same disease as they have different gene structure. At the same time, medication depends on how well patients can respond to its dosage. Hence, the need for precision medicine. Market Research Future (MRFR), in their report, has included various drivers and segments that can produce a reliable prediction for the future market. Prevalent diseases such as cancer, diabetes, and others are boosting the precision medicine market as treatment of such diseases gets a better result with personalized medicine structure. Furthermore, its impact can significantly lower the cost of treatment.
However, a personal data breach can be seen as a major precision medicine market growth prohibition. The diagnostic cost can incur a high cost, stringent government policies, the risk with hardware and software failure, and lack of medical framework can hold back the market during the forecast period.
Key Players for Global Precision Medicine Market:
Abbott Laboratories, Almac Group, Ltd., Asuragen, Inc., Biomérieux Sa, Cepheid Inc., Cetics Healthcare Technologies Gmbh, Ge Healthcare, Glaxosmithkline Plc, Johnson & Johnson, Laboratory Corporation Of America Holdings, Medtronic, Novartis, Pfizer Inc., Qiagen, Biobase Gmbh, Quest Diagnostics Inc, Randox Laboratories Ltd., Sanofi Pharma, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Ab-Biotics Sa, Caris Life Sciences, Healthcore, Inc., Ibm, Innventis, Intel Corporation, Molecular Health Gmbh, Precision For Medicine
Key Findings:
  • The global precision medicine market is expected to reach USD 88.64 billion by 2025.
  • By ecosystem diagnostic tool companies holds the largest market share of precision medicine market and is expected to reach USD 27.56 billion by 2025.
  • By sub-market, company diagnostics holds the largest market share of precision medicine market and is expected to reach USD 21.32 billion by 2025.
Segmentation
The global precision medicine market has been segmented into ecosystem players, sub-markets, and therapeutics.
Based on ecosystem players, the global market has been segmented into pharmaceuticals and biotechnology companies, diagnostic companies, healthcare IT specialists/big data companies, and clinical laboratories. The diagnostic tool companies segment accounted for a market value of USD 16.27 million in 2017.
Based on sub-markets, the global market has been segmented into companion diagnostics, biomarker-based test, targeted therapeutics, pharmacogenomics (PGX), molecular diagnostics, and others.
Based on therapeutics, the global market has been segmented cancer/oncology, cardiovascular disease (CVD), central nervous system, infectious diseases, and others.
Regional Analysis
Globally North America is the largest market for global precision medicine. Europe is the second-largest market for global precision medicine. The near future market for precision medicine will be dominated by the developed regions with developing regions providing a supporting role only. However the developing regions market particularly Asia Pacific will be the fastest growing and is likely to be the key to the future.
Browse Complete 313 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/precision-medicine-market-925
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Plasma Fractionation Market Trends and Drivers Analysis 2019 To 2023

Increasing prevalence of immunodeficiency disorders and rising healthcare expenditure are also boosting the plasma fractionation market in the US region. According to the 2018 study published in the Allergy, Asthma & Clinical Immunology journal, the estimated overall prevalence of immunoglobulin A (IgA) deficiency in the US was approximately 1 in 300 to 1 in 500 persons.
Rising participation of market players is one of the key factors driving the plasma fractionation market. For instance, in 2018, Grifols acquired 24 plasma donation centers in the United States operated by Biotest Pharmaceuticals Corp. for USD 286 million. With this acquisition, Grifols now owns 249 plasma donation centres to increase its supply of plasma proteins used for therapeutic purposes.
In plasma fractionation process protein products are fractionated from human plasma for the prevention, and treatment of life-threatening conditions such as congenital deficiencies, immunologic disorders, and others.
Global Plasma Fractionation Market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 18073 million in 2017 and is projected to grow at a CAGR of 6.5% over the forecast period.
Various other factors such as increasing geriatric population, technological advancements, emerging markets in APAC and RoW, rising plasma collection, and increasing prevalence of respiratory and autoimmune disorders are also expected to propel the growth of the market.
However, the emergence of recombinant alternatives, high cost of advanced products, and unfavourable reimbursement policies can hamper the market growth over the forecast period.
Segmentation
The global plasma fractionation market is segmented based on product, application, end user, and region.
The global market for plasma fractionation, by product is segmented into immunoglobulin, coagulation factor concentrates, albumin, protease inhibitors, and others. The immunoglobulin segment is further classified as intravenous immunoglobulin (IVIG), subcutaneous immunoglobulin (SCIG), and others. The coagulation factor concentrates segment is further classified as Factor VIII, Factor IX, Von Willebrand Factor, Prothrombin Complex Concentrate, Fibrinogen Concentrates, and Factor XIII.
Based on application, the market is segmented into immunology, neurology, hematology, critical care, pulmonology, rheumatology, hemato-oncology, and others.
Based on end user, the market is segmented into hospitals & clinics, clinical research laboratories, academic institutes, and others.
In the current scope of the study, the above-mentioned segments are covered into the four global regions, namely the Americas, Europe, Asia-Pacific and the Middle East & African region.
The plasma fractionation market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European plasma fractionation market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The plasma fractionation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The plasma fractionation market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The Americas dominated the global market for plasma fractionation owing to the presence of major market players and increasing prevalence of immunodeficiency disorders within the region. According to the 2018 study published in the Allergy, Asthma & Clinical Immunology journal, the estimated overall prevalence of immunoglobulin A (IgA) deficiency in the US was approximately 1 in 300 to 1 in 500 persons.
In 2017, it was estimated that Europe stood second in the global plasma fractionation market. This can be attributed to the increasing technological advancements, and rising R&D investments.
Asia Pacific was projected to be the fastest growing region in 2017. Increasing healthcare expenditure drives the regional markets of the Asia Pacific region. According to the Australian Institute of Health and Welfare, from 2015 to 2016, the total health expenditure was USD 181 billion. Out of this, USD 69 billion was spent on hospitals, which is a real increase of USD 2 billion from the previous year. During the same years, non-government sources spent USD 55.8 billion on health.
On the other hand, the Middle East and Africa held least share in the global plasma fractionation market due to inadequate economic development, especially within the African region.
Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/plasma-fractionation-market-7397
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Dental Bone Graft Substitutes Market to show steady growth, 2019

Market Scenario:
Global dental bone graft substitutes market is expected to grow significantly over the forecast period. It is anticipated that the market held value of USD 461.3 million in 2017 and is projected to grow at a CAGR of 9.4% over the forecast period.
The increasing incidence of oral diseases such as, dental caries and periodontal diseases, growing ageing population, and growing medical tourism in developing countries are expected to drive the growth of market. Dental tourism is increasing because dental patients mostly from a developed country are getting attracted towards other developing countries. Dental patients prefer to travel to the countries because these countries are providing cost effective and high-quality treatment. Mostly, the treatments in the dental tourism centers around the demand for dental implants. Countries like Hungary, India, South Korea and Turkey are increasingly gaining popularity in the area of dental tourism for their low cost and effective oral health treatment. On other hand, lack of proper reimbursement and stringent regulations can restrain the market growth over the assessment period. Moreover, increasing burden of oral diseases drive the growth of the market. According to Centers for Disease Control and Prevention (CDC), about 64.7 million Americans were suffered with periodontal disease.
Global Dental Bone Graft Substitutes, by Key Players
  • Biohorizons Iph, Inc. (US)
  • Geistlich Pharma AG (Switzerland)
  • Dentsply Sirona (US)
  • Institut Straumann AG (Switzerland)
  • Medtronic Plc (US)
  • Zimmer Biomet Dental (US)
  • Dentium (South Korea)
  • LifeNet Health (US)
  • Orthogen, LLC (US)
Segmentation
The global dental bone graft substitutes market has been segmented into type, application, and end user.
Based on type, dental bone graft substitutes market is segmented into allograft, xenograft, alloplast, and others.
Based on application, dental bone graft substitutes market is segmented into ridge augmentation, sinus lift, socket preservation, periodontal defect, and implant bone regeneration.
Based on end user, dental bone graft substitutes market is segmented into dental clinics, hospitals, and others. The dental clinics segment is expected to account for the largest share segment of the market in 2017.
The dental bone graft substitutes market segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The dental bone graft substitutes market in the Americas further segmented into North America and South America, with the North American market divided into the US and Canada.
The European dental bone graft substitutes market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The dental bone graft substitutes market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The dental bone graft substitutes market in the Middle East & Africa segmented into the Middle East and Africa.
Regional Summary
Geographically, the Europe is expected to dominate the global dental bone graft substitutes market owing to the presence of well-established players, increasing incidence of oral diseases namely, dental caries and periodontal diseases, and growing ageing population. The Americas is expected to hold the second largest position in the global dental bone graft substitutes market. Asia-Pacific is expected to be the fastest growing market owing to growing medical tourism in developing countries and growing ageing population. Furthermore, the Middle East and Africa region is expected to account for the least market share in the global dental bone graft substitutes market.
Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/dental-bone-graft-substitutes-market-7321

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Endovascular Aneurysm Repair Devices Market 2019 - Opportunity, Driving Trends and deep study 2023

Endovascular aneurysm repair (EVAR) is a collective term for all treatments that are directed to surgically cure an aortic aneurysm located in the patient’s abdomen. Factors such as reduced recovery times, low-cost hospitalization charges, and technological advancements in repair devices are expected to drive the growth of the market.
The global endovascular aneurysm repair devices market is currently dominated by many market players. The key players in the market are engaged in new product launches and strategic collaborations to strengthen its market position. For instance, in April 2018, Vascutek Ltd. and Bolton Medical, subsidiaries of Terumo Corporation, have merged into Terumo Aortic. Combining the aortic companies into a single business, Terumo Corporation aims to grow its presence in the aortic and vascular implants market.
It is estimated that the global endovascular aneurysm repair devices market is expected to record a CAGR ~ 6.4 % during the forecast period of 2018 to 2023.
Key players
  • Cardiatis SA,
  • Cardinal Health,
  • Cook Medical LLC,
  • Endologix, INC.,
  • Jotec GmbH,
  • Medtronic plc,
  • Terumo Corporation,
  • L. Gore & Associates, Inc.,
  • BiFlow Medical Ltd,
  • Boston Scientific Corporation,
  • Braile Biomédica,
  • Endoluminal Sciences Pty Ltd,
  • Endospan Ltd.,
  • Getinge AB,
  • Lemaitre Vascular Inc.
Segmentation
The global endovascular aneurysm repair devices market has been segmented into indication, site, anatomy, and products.
The market, on the basis of indication, has been segmented into the abdominal aortic aneurysm, thoracic aortic aneurysm and others.
The market, based on thoracic aortic aneurysm, has been further segmented into ascending aortic aneurysm, descending aortic aneurysm, thoracoabdominal aortic aneurysm, and thoracic arch aortic aneurysm.
The market, on the basis of the site, has been segmented into infrarenal and pararenal.
The market, based on pararenal site, has been sub-segmented into juxtarenal and suprarenal.
The market, on the basis of anatomy, has been segmented into traditional and complex.
The market, on the basis of products, has been segmented into percutaneous EVAR, fenestrated EVAR, aortic stents and TAA grafts, and others.
Regional Market Summary
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The endovascular aneurysm repair devices market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The Americas is expected to dominate the global endovascular aneurysm repair devices market owing to increasing geriatric population, and well-developed healthcare sector. With the increase in the geriatric population, the prevalence of aneurysms is also expected to rise. The Centers for Disease Control and Prevention (CDC) ranks abdominal aortic aneurysm as one of the top 15 causes of mortality in the United States, but only for those between 85 and 89 years. According to the Centers for Disease Control and Prevention, aortic aneurysms were the primary cause of 9,863 deaths in 2014 in the US.
Europe is expected to hold the second largest position in the global endovascular aneurysm repair devices market. The market growth in this region is attributed to the growing prevalence of aneurysms, availability of funds for research, and favorable reimbursement scenario.
On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to the growing government initiatives for the healthcare sector.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies.
Browse Complete 100 Pages Premium Research Report Enabled with 110 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/endovascular-aneurysm-repair-devices-market-6485
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Current and forthcoming Overactive Bladder Treatment Market size in terms of volume and value 2019

Market Scenario:
Overactive bladder is a condition that occurs in various diseases such as Parkinson's disease, multiple sclerosis, stroke, and others. Rise in prevalence of these diseases and rapid increase in the global geriatric population are inducing high demand for effective treatment of overactive bladder, which in turn is propelling the growth of the global overactive bladder treatment market. Increased marketing activities, availability of affordable treatments and development of innovative treatment procedures are also fueling the growth of the global overactive bladder treatment market. However, low penetration of treatment options in the healthcare sector and lack of awareness among the population of the underdeveloped countries are restricting the expansion of the global overactive bladder treatment market during the assessment period.
The global overactive bladder treatment market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global overactive bladder treatment market is expected to register a CAGR of ~ 3.1% during the forecast period of 2018–2023.
Despite the drivers, lack of awareness in developing countries and undesired systemic effects of some current treatment options may hinder the growth of the market during the assessment period.
Company Profiles    
  • Astellas Pharma Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical
  • Allergan, Plc. 
  • Mylan N.V. 
  • Endo International Plc 
  • Hisamitsu Pharmaceutical Co., Inc.
  • Sanofi S. A.
  • Aurobindo Pharma Limited 
  • Johnson & Johnson
  • Intas Pharmaceuticals Ltd. 
  • Apotex Inc. 
  • Macleods Pharmaceuticals Ltd. 
  • Medtronic PLC
  • Cogentix Medical, Inc.
  • Others
Segmentation
The global overactive bladder treatment market is segmented on the basis of pharmacotherapy, non-pharmacological treatment, and disease.
On the basis of pharmacotherapy, the market is classified into anticholinergics, Botox, mirabegron, neurostimulation, and others. Further, anticholinergics are classified into solifenacin, oxybutynin, fesoterodine, darifenacin, tolterodine, trospium, and others.
The global overactive bladder treatment market on the basis of non-pharmacological treatment is segmented into dietary and fluid modifications, behavioral therapy, pelvic floor muscle rehabilitation, and others.
On the basis of disease, the market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. Further, the neurogenic overactive bladder is segmented into the overactive bladder in Parkinson’s disease, the overactive bladder in stroke, the overactive bladder in spinal cord injury, and overactive bladder in other disorders.
Geographically, the global overactive bladder treatment market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The overactive bladder treatment market in the Americas is further segmented into North America and South America. North America is further classified as the US and Canada.
The overactive bladder treatment market in Europe is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe.
The overactive bladder treatment market in Asia-Pacific is segmented into Japan, China, India, Republic of Korea, Australia, and the rest of Asia-Pacific.
The overactive bladder treatment market in the Middle East and Africa is segmented into the Middle East and Africa.
Regional Market Summary
The global overactive bladder treatment market consists of four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa. North America is anticipated to dominate the market in the Americas owing to the increasing geriatric population, growing occurrences of OAB, and the availability of numerous healthcare coverage systems such as Medicare.
Europe is anticipated to hold the second position in the global overactive bladder treatment market. It is estimated that the market growth in this region is attributed to the rising incidences of OAB and availability of reimbursement for certain treatment options. For instance, the UK’s National Institutes for Health and Care Excellence (NICE) provides reimbursement for the Botox therapy.
The overactive bladder treatment market in Asia-Pacific consists of countries, namely, China, Japan, the Republic of Korea, India, Australia, and the rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the growing prevalence of bladder overactivity, rising geriatric population, rising healthcare expenditure, and increasing awareness about overactive bladder condition.
The Middle East and Africa are likely to hold the least share in the global overactive bladder treatment market. In this region, the Middle East is expected to dominate owing to the rising healthcare expenditure and rising occurrences of neurological diseases, especially among the aged population.
Browse Premium Research Report with Tables and Figures @ https://www.marketresearchfuture.com/reports/overactive-bladder-treatment-market-6248
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Intussusception Market to show steady growth, 2019

Market Scenario
According to the National health statistics, intussusception affects about 1 in every 1,900 children in the US. Its incidence is more common in children between one to five months, peaking at four to nine months of age, and then gradually declines at around 18 months. Intussusception affects boys and girls, with a ratio of approximately 3:1.
The global intussusception market is expected to reach USD 6.3 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.4 % during the forecast period 2017-2023.
Intussusception, also called bowel obstruction, is a potentially life-threatening condition caused by folding of one part of the intestine into another part, which causes a blockage in the intestine. The blockage hamper the excretion process. Intussusception is dominant in children of age 2 months-2 years. However, adults may also be affected by the intussusception. It commonly occurs where the small and large intestines meet. Additionally, it can occurs due to various causes such as tumors, inflammation, Meckel's diverticulum, duplication, appendix, hyperplasia of Peyer's patches, intestinal surgery, polyps, tumors, inflammation, etc.
It block the blood supply to intestine and causes tissue death. Tissue death can lead to infection, internal bleeding, tearing, damage to the intestines, and peritonitis. The primary symptoms of intussusception include acute abdominal pain, vomiting, nausea, lethargy, blood or mucus in the stools, constipation, etc. The risk factors for intussusception are age, sex, abnormal intestinal formation at birth, a family history, etc.
The market is growing at a very steady pace. Companies are opting various business strategies to capture a reasonable amount of share in the market. Product development represents the best strategy for dominating the market as surgery is the definitive treatment for intussusception market. The advent of minimally invasive treatment and diagnostic techniques such as computed tomography has changed the market landscape for to a large extent. Miniaturization of surgical instruments and development of minimal invasive treatment such as robotic laparoscopy is expected to drive the future market in the developed regions of North America and Europe. The cost of the product will be a decisive factor in the developing regions such as Asia Pacific and, especially, Africa. The growing demand for better minimally invasive surgical procedures is the greatest unmet need of the market.
The developments in the surgery segment, such as minimal invasive laparoscopy surgery, is driving the global intussusception market. The drug segment is, however, suffering from market fragmentation, which has put pressure on the price margins. The loss of patents and the rise of counterfeited drugs has also restricted the market growth. The other market constrains are high cost of surgery and complications of the surgery. Market development represents the best strategy for the market growth. The market is expected to witness exponential growth over the review period owing to minimal invasive surgical procedures.
Key Players in the Global Intussusception Market
Some of the key players profiled in the report are Pfizer, Inc., Janssen Pharmaceuticals, Inc., Abbott, GlaxoSmithKline plc, sanofi-aventis U.S. LLC. , Novartis AG, Bayer AG, FUJIFILM Holdings Corporation, General Electric Company, Shimadzu Corporation, Carestream Health, Bristol-Myers Squibb Company, and others.
Segments of Global Intussusception Market
The global intussusception market has been segmented on the basis of type, diagnosis, treatment, and end user.
Based on the type, the market has been segmented as Ileoileal, Ileocolic, Ileo-ileo-colic, and others.
Based on the surgery, the market has been segmented as surgery, drugs, and others.
Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.
Based on the diagnosis, the market has been segmented as barium enema, ultrasound, X-ray, computerized tomography (CT), and others.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/intussusception-market-4511
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)